






































FoxO TFs in longevity and aging-associated disease 
 
The role of FoxO TFs in lifespan control was first 
established in C. elegans, where reduction of IIS or 
ablation of the germline extends lifespan in a DAF-
16/FoxO-dependent manner [1, 2]. FoxO also promotes 
lifespan extension in Drosophila [3, 4]. Although 
reduction of IIS also promotes longevity in mammals 
[5, 6, 7], whether or not this requires FoxO TFs remains 
to be determined. Multiple studies indicate that specific 
FoxO polymorphisms are associated with longevity in 
cohorts of extremely long-lived humans [8, 9, 10, 11, 
12, 13], suggesting that FoxO TFs may also regulate 
lifespan in humans. 
 
 






































While a direct connection between mammalian FoxO 
TFs and lifespan control has not yet been established 
experimentally, recent work in conditional knockout 
mice supports a role for FoxO TFs in modulating 
phenotypes that are reminiscent of aging-associated 
diseases in humans. For example, mice lacking FoxO1, 
FoxO3, and FoxO4 develop thymic lymphomas and 
hemangiomas, indicating that FoxO TFs are bonafide 
tumor suppressors [14]. Furthermore, deletion of FoxO 
TFs in osteoblasts results in reduced bone mass 
secondary to increased osteoblast apoptosis [15, 16], 
suggesting that FoxO TFs are protective against 
osteoporosis. In contrast to these apparent salubrious 

























insulin/insulin‐like  growth  factor  signaling  (IIS)  pathway  and  the  germline  both  control  lifespan  by  regulating  the
subcellular localization of the FoxO transcription factor DAF‐16. Although the control of FoxO activity through modulation
of its subcellular localization is well established, nuclear translocation of FoxO is not sufficient for full FoxO activation,
suggesting  that  undiscovered  inputs  regulate  FoxO  activity  after  its  translocation  to  the  nucleus.  We  have  recently
discovered a new conserved pathway, the EAK (enhancer‐of‐akt‐1) pathway, which acts in parallel to the Akt/PKB family of






  www.impactaging.com AGING, October 2010, Vol. 2 No 10
   
www.impactaging.com                   742                                    AGING, October 2   010, Vol.2   No.10dysregulation similar to that observed in Type 2 
diabetes, as FoxO1 haploinsufficiency protects mice 
against insulin resistance induced by a high-fat diet 
[17], and both liver-specific and osteoblast-specific 
FoxO1 deletion ameliorate glucose intolerance in mouse 
models of insulin resistance [18, 19, 20]. Thus, in 
mammals, FoxO TFs have context-dependent effects on 
the development of phenotypes associated with age-
related disease. Elucidating the regulatory mechanisms 
that maintain the balance of FoxO TF activity may 
prove to be crucial for understanding and combating the 
progression of age-related disease. 
 
DAF-16/FoxO regulation in the control of C. elegans 
lifespan 
 
DAF-16/FoxO is required for C. elegans lifespan 
modulation by IIS and the germline [1, 2], as well as in 
some contexts of dietary restriction [21]. Reduction of 
IIS and ablation of the germline both extend lifespan by 
increasing DAF-16/FoxO activity. Neither intervention 
increases lifespan in daf-16/FoxO null mutants [1, 2], 
indicating that DAF-16/FoxO is the critical target of IIS 
and the germline in lifespan control. 
 
IIS and the germline both inhibit DAF-16/FoxO by 
promoting its cytoplasmic sequestration. When IIS is 
reduced, or when the germline is ablated, DAF-
16/FoxO translocates to the nucleus [22, 23, 24], where 
it executes gene regulatory programs that promote 
longevity. IIS induces the phosphorylation of DAF-
16/FoxO by Akt/Protein Kinase B (PKB) [23, 24], 
which results in the cytoplasmic sequestration of DAF-





















teins [25, 26]. The molecular requirements for DAF-
16/FoxO nuclear translocation in the context of reduced 
IIS have not been fully delineated but may include 
serine-threonine kinases such as JNK-1 [27] and CST-1 
[28]. 
 
How the germline promotes the cytoplasmic 
sequestration of DAF-16/FoxO is not entirely under-
stood. Notably, germline ablation extends lifespan in 
animals with reduced IIS [2]. In animals lacking a germ-
line, translocation of cytoplasmic DAF-16/FoxO to the 
nucleus requires the nuclear receptor DAF-12 [29] and its 
steroid hormone ligands [29, 30], which are known as 
dafachronic acids (DAs) [31]. The conserved protein 
KRI-1 is required for DAF-16/FoxO nuclear transloca-
tion in animals lacking a germline but largely dispensable 
for DAF-16/FoxO nuclear localization in animals with 
reduced IIS [29]. In aggregate, these observations suggest 
that IIS and the germline control the subcellular 
localization of DAF-16/FoxO via distinct mechanisms. 
 
Nuclear translocation is not sufficient for full DAF-
16/FoxO activation 
 
Although nuclear localization of DAF-16/FoxO is 
clearly necessary for DAF-16/FoxO-dependent lifespan 
extension, multiple lines of evidence indicate that it is 
not sufficient for full DAF-16/FoxO activation. For 
example, a DAF-16/FoxO mutant lacking all four 
canonical Akt/PKB phosphorylation sites localizes to 
the nucleus but fails to fully extend lifespan [24, 29]. 
This indicates that a second pathway acts in parallel to 

























Gene Predicted  product Human  ortholog  Expression  pattern 
eak-1  ? ?  ? 
eak-2 hsd-1  Sdr42e1 XXX  cells 
eak-3  N-myristoylated protein  ?  XXX cells 
eak-4  N-myristoylated protein  ?  XXX cells 
eak-5 sdf-9  ? XXX  cells 
eak-6  Protein tyrosine phosphatase  ?  XXX cells
1 
eak-7  N-myristoylated TLDc protein  KIAA1609  XXX cells, neurons, 




























A genetic screen for molecules that regulate nuclear 
DAF-16/FoxO activity 
 
To identify components of this parallel DAF-16/FoxO 
regulatory pathway, we exploited the fact that in larvae, 
DAF-16/FoxO promotes developmental arrest in an 
alternative larval stage called dauer that is morpho-
logically distinct from reproductively developing larvae 
[32]. We performed a genetic screen for mutants that 
enhance the weak dauer-constitutive phenotype of an 
akt-1 null mutant (eak  screen). We identified 21 
independent mutants that define seven eak genes, six of 
which have been cloned (Table 1) [33, 34, 35]. 
Strikingly, five of the six cloned eak genes are 
expressed specifically in the two endocrine XXX cells 
[34, 35, 36]; in contrast, eak-7 is expressed in the XXX 
cells as well as multiple other tissues [33]. The 
phenotypic similarity of all eak single mutants and the 
observation that no eak;eak double mutant combination 
tested to date exhibits phenotypic enhancement 
compared to eak single mutants indicate that the EAK 
proteins are components of a single pathway. 
 
EAK proteins and AKT-1 both control DAF-16/FoxO 
target gene expression. However, in contrast to AKT-1, 
which inhibits DAF-16/FoxO activity by promoting its 
translocation from the nucleus to the cytoplasm, EAK 
proteins inhibit nuclear DAF-16/FoxO activity without 
influencing its subcellular localization [33, 34, 35]. 


























a new conserved endocrine pathway that acts in parallel 
to Akt/PKB to regulate the activity of nuclear DAF-
16/FoxO. Two eak genes, eak-2/hsd-1 and eak-7, have 
putative mammalian orthologs based on comparative 




EAK-2 is allelic to the 3β-hydroxysteroid dehydro-
genase family member HSD-1 [34, 37]. HSD-1 is 
thought to participate with the cytochrome P450 DAF-9 
in the biosynthesis of Δ
4-dafachronic acid (Δ
4-DA) [31, 
37]; the related steroid Δ
7-DA is synthesized by the 
Rieske oxygenase family member DAF-36 and DAF-9 
[31, 38]. Both Δ
4- and Δ
7-DA are high-affinity ligands 
for the nuclear receptor DAF-12 [31]. 
 
The identification of hsd-1 mutations in the eak screen 
implicates steroid hormone signaling in the regulation 
of nuclear DAF-16/FoxO activity. In support of this, we 
have shown that daf-36  and  daf-9  mutations also 
enhance the akt-1 dauer-constitutive phenotype [34]. 
Furthermore,  hsd-1 mutation synergizes with akt-1 
mutation to increase DAF-16/FoxO target gene 
expression, and DAF-16/FoxO target gene expression in 
hsd-1;akt-1 double mutants requires not only DAF-
16/FoxO but also DAF-12 [34]. Thus, DAF-12 may act 
in parallel to DAF-16/FoxO to coregulate a subset of 
DAF-16/FoxO target genes. hsd-1 is expressed 
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findings suggest that DAs synthesized in the XXX cells 
act through DAF-12 and in parallel to AKT-1 to 
coregulate DAF-16/FoxO target gene expression. In 
contrast to akt-1  mutation,  hsd-1 mutation does not 
promote nuclear translocation of a functional DAF-
16::GFP fusion protein [34], indicating that HSD-1 
controls DAF-16/FoxO activity without promoting 
DAF-16/FoxO translocation to the cytoplasm. 
 
The role of HSD-1 in lifespan control is complex. In 
wild-type animals, HSD-1 does not have a major impact 
on adult lifespan. However, in animals with reduced 
IIS, HSD-1 is required for full lifespan extension [34]. 
This is reminiscent of the requirement for DAF-36 and 
DAF-9 in lifespan extension induced by germline 
ablation [29, 40]. Surprisingly, in contrast to daf-36 and 
daf-9 mutations, which substantially shorten the 
lifespan of animals lacking a germline [29, 40], hsd-1 
mutation does not affect lifespan extension induced by 
germline ablation [34]. This may be a consequence of 
the relative potencies of Δ
4- and Δ
7-DA and/or the 
anatomical source of distinct DAs (XXX cells vs. 
hypodermis and somatic gonad). Alternatively, HSD-1 
may participate in the biosynthesis of a different steroid 
hormone that is required for full lifespan extension in 
the context of reduced IIS but dispensable for lifespan 




In contrast to hsd-1 and other eak single mutants, eak-7 
single mutants live approximately 25% longer than 
wild-type animals, and this lifespan extension requires 
DAF-16/FoxO as well as the DAF-16/FoxO cofactors 
HSF-1 and SMK-1 [33]. As is the case for other EAK 
proteins, EAK-7 inhibits nuclear DAF-16/FoxO activity 
without influencing its subcellular localization [33]. 
Notably, although eak-7 mutation strongly enhances the 
dauer-constitutive phenotype of akt-1 mutants, its 
enhancement of lifespan extension in akt-1 mutants is 
relatively modest [33]. This is likely a consequence of 
the influence of the germline on DAF-16/FoxO 
subcellular localization; since the germline promotes the 
cytoplasmic sequestration of DAF-16/FoxO [24], akt-1 
mutation may not increase nuclear concentrations of 
DAF-16/FoxO to the extent that it does in early larval 
stages, before the germline has proliferated. In 
accordance with this, eak-7 mutation strongly enhances 
lifespan extension (by ~50-80%) in animals lacking a 
germline [33]. 
 
How EAK-7 controls nuclear DAF-16/FoxO activity is 
unclear. EAK-7 contains a consensus N-myristoylation 
(N-myr) motif and a TLDc (TBC- and LysM-domain-
containing) domain [33], the function of which is poorly 
understood. Interestingly, a functional EAK-7::GFP 
fusion protein localizes to the plasma membrane and 
does not appear to translocate in adult animals [33]. 
Thus, EAK-7 likely regulates nuclear DAF-16/FoxO 
activity indirectly. eak-7 mutation increases steady-state 
DAF-16/FoxO protein levels in akt-1 mutants without 
altering  daf-16/FoxO  transcript levels, suggesting that 
EAK-7 may modulate DAF-16/FoxO synthesis or 
turnover [33]. A hypothetical model of how EAK-7 
controls DAF-16/FoxO activity in concert with IIS and 
the germline is shown in Figure 1. 
 
Potential role of the EAK pathway in diseases 
associated with aging 
 
Although studies in mammalian cells have also 
implicated a regulatory input that controls the activity of 
FoxO TFs that are localized to the nucleus [41], the 
nature of this input is obscure. Our data suggest that the 
putative HSD-1 and EAK-7 mammalian orthologs 
Sdr42e1 and KIAA1609 may be components of this 
input. Recent work on mice harboring conditional 
knockout alleles of FoxO1 point to a potential role for 
FoxO TFs in the pathogenesis of Type 2 diabetes [17, 
18, 19, 20], cancer [14], and osteoporosis [16, 42]; thus, 
it is conceivable that the EAK pathway may influence 
the pathogenesis of these aging-associated diseases. 
 
The function of the putative mammalian HSD-1 
ortholog Sdr42e1 is not known. Sdr42e1 mRNA is 
expressed in a limited number of mouse tissues, with 
strikingly high expression in liver [43], where FoxO1 
plays an important role in metabolic homeostasis [19, 
20]. In contexts of insulin resistance, reduction of 
hepatic FoxO1 activity substantially ameliorates 
dysregulation of glucose metabolism in mice [19, 20]. 
Since FoxO1 is nuclear in these circumstances [44], 
Sdr42e1 could play an important role in controlling 
hepatic FoxO1 activity and glucose homeostasis. The 
putative EAK-7 ortholog KIAA1609 is widely 
expressed in mouse tissues and is also present in mouse 
liver [43], indicating that KIAA1609 may also influence 
glucose metabolism in the context of insulin resistance. 
Both Sdr42e1 and KIAA1609 are expressed in mouse 
osteoblasts [43], where FoxO TFs promote the 
maintenance of normal bone mass and control 
metabolism nonautonomously through regulation of 
osteocalcin activity [16, 42]; thus, EAK pathway 
activity in osteoblasts could influence the development 
of both osteoporosis and Type 2 diabetes. Intriguingly, 
KIAA1609 is highly expressed in mouse retinal 
pigment epithelium (RPE), where FoxO1 and FoxO3 
are also expressed [43]. Although nothing is known 
about the function of FoxO TFs in RPE, the extreme 
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that the EAK pathway could be important in regulating 
FoxO activity in RPE. 
 
It is noteworthy that the genes encoding human Sdr42e1 
and KIAA1609 lie within 2.5 megabases of each other 
at chromosome 16q23. Copy number variation in this 
genomic region could affect both genes coordinately, 
changing baseline EAK pathway activity (and, in turn, 




The EAK pathway is a new conserved FoxO regulatory 
input that acts in parallel to Akt/PKB and the germline 
to control C. elegans lifespan. Continued investigation 
of the C. elegans EAK pathway promises to reveal new 
insights into mechanisms of FoxO regulation. In light of 
the potential role of FoxO TFs in mammalian aging and 
the pathogenesis of aging-associated diseases, EAK 
proteins could emerge as promising targets for the 
development of new drugs to treat Type 2 diabetes, 
cancer, and osteoporosis. Studies of Sdr42e1 and 
KIAA1609 function in mouse models of aging and 
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